| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-01-13 | Inflectis Bioscience (France) | €1.75 million | financing round | Bpifrance (France) investor Participations Besançon (France) GO Capital (France) | Rare diseases - Genetic diseases - Neurodegenerative diseases | Financing round |
| 2015-01-12 | Capricor Therapeutics (USA - CA) | $1 million | private placement | CureDuchenne Ventures (USA - CA) | Rare diseases - Neuromuscular diseases | Private placement |
| 2015-01-12 | UroSens (UK) | £2 million | financing round | Longwall Venture Partners (UK) Northstar Ventures (UK) Esperante BV (The Netherlands) Cambridge Capital Group (UK) and other existing shareholders. | Cancer - Oncology - Diagnostic | Financing round |
| 2015-01-12 | RedXPharma (UK) | £15 million | IPO | Cancer - Oncology - Infectious diseases | IPO | |
| 2015-01-09 | MaaT Pharma (France) | € 1 million | financing round | Seventure Partners (France) | Gastrointestinal diseases - Infectious diseases | Financing round |
| 2015-01-07 | GenSight Biologics (France) Pixium Vision (France) Fondation Voir et Entendre (France) | € 18.5 million | grant | BpiFrance (France) | Ophtalmological diseases | Grant |
| 2015-01-07 | Affimed (Germany) | € 2.4 million ($3 million) | grant | German Federal Ministry of Education and Research (BMBF) (Germany) | Cancer - Oncology | Grant |
| 2015-01-06 | AveXis (USA - CA) | $10 million | series C financing round | Deerfield Management (USA) Roche Venture Fund (Switzerland) | Rare diseases - Neuromuscular diseases - Neurodegenerative diseases | Series C financing round |
| 2015-01-06 | Seres Health (USA - MA) | $ 65 million | series D financing round | Nestlé Health Science (Switzerland) | Infectious diseases - Inflammatory diseases - Metabolic diseases | Series D financing round |
| 2015-01-05 | Moderna Therapeutics (USA - MA) | $450 Million | Viking Global Investors LP (UK-USA), Invus (USA - MA), RA Capital Management (USA - MA), Wellington Management Company (USA - MA), AstraZeneca (UK), Alexion Pharmaceuticals (USA - CT), additional undisclosed existing investors | Cancer - Oncology - Rare diseases - Cardiovascular diseases - Infectious diseases | Fundraising | |
| 2015-01-02 | Apeptico (Austria) | grant | The Wellcome Trust (UK) | Rare diseases | Grant | |
| 2015-01-01 | Orphazyme (Denmark) | € 20 million | series B financing round | Kurma Partners (France) Idinvest Partners (France) Novo A/S (Denmark) Sunstone Capital (Denmark) Aescap Venture (The Netherlands) | Genetic diseases - Rare diseases | Series B financing round |
| 2014-12-23 | Pieris (Germany) | $13.56 million | private placement | Private placement | ||
| 2014-12-22 | NewLink Genetics (USA - IO) Merck&Co (USA - NJ) | $30 million | grant | Biomedical Advanced Research and Development Authority (USA) | Infectious diseases | Grant |
| 2014-12-18 | Nutrinia (Israel) | $12 million | series C financing round | OrbiMed (USA - NY) Jacobs Investment Company (USA - FL) Pontifax (Israel) | Rare diseases - Gastrointestinal diseases - Digestive diseases | Series C financing round |
| 2014-12-18 | Ecrins Therapeutics (France) | fundraising | WiSEED (France) | Cancer - Oncology | Fundraising | |
| 2014-12-17 | IMMUNOSHAPE consortium (Midatech Pharma (UK) | €3.8 million | grant | Allergic diseases - Autoimmune diseases - Cancer - Oncology | Grant | |
| 2014-12-16 | GSK (UK) University of Oxford (UK) Centre Hospitalier Universitaire Vaudois (Switzerland) Bernhard-Nocht Institute (Germany) | €15.1 million | grant | European Commission’s Horizon 2020 programme | Infectious diseases | Establishment of a new subsidiary in the EU |
| 2014-12-16 | Kymab (UK) | grant | The Wellcome Trust (UK) | Infectious diseases | Grant | |
| 2014-12-15 | BerGenBio (Norway) | NOK90 million ($15 million - €9.8 million) | private placement | Cancer - Oncology - Rare diseases | Private placement |
